Table 1.

Patient characteristics and adverse events observed

IDAgeT.N.MDiagnoseInvasion depthHPV typeTime (mo)N vaccAdverse eventsStudy statusFU (mo)Clinical status (mo)
100331B1.0.0SCC9 mm16424Fever, flu-like symptoms, itching injection site, swelling injection site; burning eyesCompleted27Recurrence (7)
1010Withdrawn
102591B1.0.0SCC6 mm1644Fever, flu-like symptoms, itching injection site, swelling injection site, itching neck, back, breastCompleted24Free of disease
103351B1.0.0SCC13 mm1633Fever, swelling injection site, itching fingers and feetNot completed9Recurrence (0)
1040Withdrawn
105341B1.0.0SCC8 mm1664Swelling injection siteCompleted13Free of disease
106581B1.0.0ADCnot determined1643Flu-like symptoms, swelling injection siteNot completed0Lost in FU
107331B1.0.0ADC4.5 mm1644Swelling injection siteCompleted10Free of disease
  • NOTE: The cervical cancer tumor was histologically diagnosed as squamous cell carcinoma or adenocarcinoma. The time period (in months) between the treatment of cervical cancer and the first vaccination is given. Patients were scheduled to receive a total of four vaccinations; the number of vaccinations is given. All adverse events of the vaccine are temporarily, and systemic side effects like fever and flu-like symptoms were readily treated with paracetamol. The swelling at the injection site was not painful and probably due to the adjuvant Montanide ISA-51 in the vaccine. The follow-up of these patients after the last vaccination is indicated in months. Patient ID103 died 9 mo after the last vaccination because of local recurrence. The clinical status is given, and the time period (in months) after the last vaccination between brackets.

    Abbreviations: SCC, squamous cell carcinoma; ADC, adenocarcinoma; N vacc, number of vaccinations; FU, follow-up.